<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03998228</url>
  </required_header>
  <id_info>
    <org_study_id>TSE_2019_11</org_study_id>
    <nct_id>NCT03998228</nct_id>
  </id_info>
  <brief_title>Association Between Dermatoporosis and Fractural Risk</brief_title>
  <acronym>DermatOstéo</acronym>
  <official_title>Association Between Dermatoporosis and Fractural Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need for new tools to identify patients who may have osteoporosis before a
      fracture occurs.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>compare fracture risk between patients with dermatoporosis and those without dermatoporosis</measure>
    <time_frame>BASELINE</time_frame>
    <description>The fracture risk will be calculated using the FRAX score. The presence of dermatoporosis will be assessed by a simple clinical examination of the forearms and defined by the presence of three clinical signs: cutaneous atrophy, Bateman purpura and presence of pseudo-stellar scars.</description>
  </primary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dermatoporosis</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Dual X-ray absorptiometry (DMO) densitometry.</intervention_name>
    <description>Simple clinical examination with forearm inspection and palpation;
Radiological examination of BMD;
Calculation of the FRAX® score;
Fact sheet on patients with dermatoporosis, proposal of a topical treatment (cosmetic cream) and completion of the questionnaire specific to dermatoporosis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Major patients who are to perform dual X-ray absorptiometry (DMO) densitometry.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged between 40 and 90 years old who has to undergo a bone densitometry (BMD)
             examination by dual X-ray absorptiometry

          -  Affiliate or beneficiary of a Social Security scheme

          -  Express consent to participate in the study.

        Exclusion Criteria:

          -  Patient benefiting from a legal protection measure

          -  Pregnant or nursing woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Laurence Salomon, MD PhD</last_name>
    <phone>0148036431</phone>
    <email>lsalomon@fo-rothschild.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas SENE, MD PhD</last_name>
    <phone>0148036226</phone>
    <email>tsene@for.paris</email>
  </overall_contact_backup>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 24, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2019</study_first_posted>
  <last_update_submitted>February 24, 2020</last_update_submitted>
  <last_update_submitted_qc>February 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

